back to US directory
us clinical guidance

Polycystic ovary syndrome

2023 international PCOS diagnostic criteria, life-course risk assessment and goal-directed reproductive, metabolic and symptom management.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adolescents and adults being assessed or treated for polycystic ovary syndrome. Diagnostic criteria differ in adolescents, and rapidly progressive androgen excess, pregnancy, another endocrine disorder or acute metabolic illness requires a separate diagnostic pathway.
sources for this section:ASRM PCOS 2023

The Bottom Line

  • In adults, diagnose PCOS after excluding relevant mimics when two of three features are present: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries on ultrasound or an accepted adult anti-M眉llerian-hormone alternative.
  • In adolescents, both hyperandrogenism and persistent ovulatory dysfunction are required; ultrasound and anti-M眉llerian hormone should not be used to diagnose PCOS because normal puberty can resemble adult criteria.
  • Assess cardiometabolic risk across body sizes with blood pressure, glycemic testing and lipids, while avoiding weight stigma and recognizing that healthy behavior has benefits even without weight loss.
  • Screen for depression, anxiety and eating disorders, and assess symptoms of obstructive sleep apnea because psychological and sleep morbidity are common and alter care priorities.
  • Match treatment to the patient鈥檚 goals: combined oral contraception can help cycles and androgen symptoms, metformin primarily addresses metabolic indications, and letrozole is first-line pharmacologic ovulation induction where no other infertility factor exists.
sources for this section:ASRM PCOS 2023

Practical clinical workflow

1
Document menstrual intervals, androgen symptoms and tempo, pregnancy goals, medications, family metabolic history, sleep, mood, eating patterns and the patient鈥檚 own priorities and language preferences.
2
Exclude pregnancy and clinically plausible alternative causes of irregular cycles or androgen excess, using targeted thyroid, prolactin, adrenal or other testing rather than an indiscriminate panel.
3
Apply age-appropriate criteria and use standardized high-quality androgen assays; in an adult, do not order both ultrasound and anti-M眉llerian hormone simply to inflate diagnostic certainty.
4
Create a plan for endometrial protection when amenorrhea is prolonged, symptom treatment when desired, metabolic prevention, contraception or fertility, and referral for nutrition or psychological support.
5
Review blood pressure, glycemia, lipids, menstrual pattern, treatment effects and changing reproductive goals over time instead of treating PCOS as a one-time fertility diagnosis.
sources for this section:ASRM PCOS 2023

Safety boundaries and escalation

  • Rapid virilization, marked androgen elevation, a new pelvic or adrenal mass symptom or abrupt symptom progression requires urgent investigation for an androgen-secreting tumor or another serious cause.
  • Prolonged untreated amenorrhea increases endometrial hyperplasia risk; new heavy or persistent abnormal bleeding requires timely endometrial-risk assessment rather than repeated reassurance.
  • Before ovulation induction, assess pregnancy, tubal or semen factors where indicated and counsel multiple-pregnancy and monitoring risks; fertility medication is not routine unsupervised cycle treatment.
  • Severe depression, suicidality, disordered eating or symptoms of significant sleep apnea require direct clinical assessment and an active referral or safety plan.
sources for this section:ASRM PCOS 2023

Localization

This US summary uses the ASRM-hosted 2023 international guideline and US terminology. Laboratory methods, medication approval, insurance coverage, fertility access and state reproductive-health rules vary; management must remain person-centered and nonstigmatizing.
sources for this section:ASRM PCOS 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Society for Reproductive Medicine and International PCOS NetworkRecommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndromepublished 2023-10-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.